Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rare inherited bleeding disorders

- PMLiVE

Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer

Company has reached milestone in stem cell therapy as it looks to broaden range beyond diabetes

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

- PMLiVE

Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

A rapid round-up of pharma, biotech and healthcare news

- PMLiVE

Novo Nordisk appoints new general manager

Pinder Sahota also becomes the corporate vice president, UK

- PMLiVE

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

The candidate is expected to start a phase II trial in the coming months

- PMLiVE

Novo Nordisk’s semaglutide obesity trial hits the mark

The injection helped adults lose up to 13.8% of their body weight in a year

- PMLiVE

Novo launches $165m antimicrobial resistance initiative

The REPAIR Fund will support groups looking to combat antibiotic resistance

Roche Basel Switzerland

Roche wins European approval for bleeding disorder treatment Hemlibra

It's the first new medicine in over 20 years to treat patients with inhibitors

- PMLiVE

Novo’s oral semaglutide ‘safe and well-tolerated’

Releases first phase III data on the new version of its diabetes treatment

Roche Basel Switzerland

Roche wins CHMP backing for Hemlibra

Haemophilia A treatment on course for European approval

Sanofi reception

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

The offer comes at a 110% premium on the Belgian biopharma’s share price

- PMLiVE

Shire claims EU approval for haemophilia A drug Adynovi

The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links